Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 22, 2008

View Archived Issues

Ispinesib appears to be well tolerated in phase I/II breast cancer study

Phase I evaluation of everolimus in hepatocellular carcinoma continues

VEGF-Trap results disappointing in phase II metastatic breast cancer study

Dose-related efficacy seen with AVE-0010 in type 2 diabetes

Panobinostat's efficacy in solid and hematologic tumors opens a new line of research in SCLC

Health Canada approves Stem Cell's phase IIa study of hCG and EPO in TBI

Upstream and Makerere University initiate animal efficacy for trypanosomiasis treatment

Takeda to initiate Japanese phase III trial of cetilistat and pay milestone payment to Alizyme

Bayer HealthCare acquires Direvo for EUR 210 million cash

Javelin completes enrollment in phase III clinical study of Dyloject in postoperative pain

Generex reaches enrollment milestone in phase III clinical trial of Oral-lyn

Y's Therapeutics completes phase IIa clinical trial of YSPSL for IRI in kidney transplants

Pluristem reports final results from preclinical animal efficacy studies of PLX-PAD

Ambrilia develops 1-month formulation of goserelin for hormone-sensitive prostate cancer

FDA issues complete response letter rejecting approval of Gilead's NDA for aztreonam lysine

Sucampo presents results from Japanese phase IIb Amitiza trial

Erbitux launched in Japan for the treatment of colorectal cancer

Recent Theravance and Argenta patents describe new treatments for respiratory disorders

FDA grants orphan drug status for patented stem cells in bone marrow transplant

Cyclacel revises operating plan to concentrate resources on advancement of sapacitabine

Sinovac initiates clinical trials in Ukraine of Healive inactivated hepatitis A vaccine

Cleveland BioLabs awarded USD 13.3 million contract for Protectan CBLB-502

Sciele reports results from two phase III studies of glycopyrrolate for pediatric patients

Three Rivers obtains commercial rights in all markets except Japan to Amgen's Infergen

Novel therapeutic agents for cardiovascular disorders covered in recent patents

Eisai describes new treatment options for multiple sclerosis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 4, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 4, 2025.
UK Biobank delivers largest metabolomics dataset of 500K profiles
BioWorld Science
It’s the biological resource that keeps on giving, and now UK Biobank has released the final tranche of data on the levels of 249 metabolites in the blood of its...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...